AzTrials
AzTrials

Bone LossNCT07540156

Evaluation of the Safety, Feasibility, and Early Clinical Outcomes of Patient-Specific Bone Defect Implants Fabricated From Titanium Alloy (Ti-6Al-4V) Using 3D Printing Technology

A study testing Patient-specific 3D-printed Ti-6Al-4V bone implant in people with Bone Loss and Bone Defects, run by VinUniversity at 1 site in Vietnam.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate the safety and feasibility of patient-specific bone defect implants fabricated from Ti-6Al-4V using 3D printing technology and to assess early clinical outcomes within the first 12 months following implantation of these customized devices. Read more about this study

Who is it for?
Any age
Conditions the study is for
Bone Loss, Bone Defects
What is being tested?
Patient-specific 3D-printed Ti-6Al-4V bone implant
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteVietnam
Study dates
1 Apr 2026to 31 Dec 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Diagnosed with a bone defect requiring surgical reconstruction, as determined by the treating orthopedic surgeon
  • Suitable candidate for implantation of a patient-specific device manufactured from Ti-6Al-4V
  • Able to undergo preoperative imaging (CT ± MRI) required for implant design
  • Willing and able to provide written informed consent
  • Willing to comply with scheduled follow-up visits and study assessments

Who cannot join

  • Active systemic or local infection at the surgical site at the time of implantation
  • Known hypersensitivity or allergy to titanium or titanium alloys
  • Severe uncontrolled comorbidities that significantly increase surgical risk (e.g., uncontrolled diabetes, severe cardiovascular disease)
  • Pregnant or breastfeeding women
  • Participation in another interventional clinical study that may interfere with the outcomes of this study
  • Inability to complete follow-up assessments within the required timeframe

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Trung Dzung Tran, Professor, PhD, MD contact

+84983762005

dung.tt@vinuni.edu.vn

Vietnam1 site
  • 3D Technology in Medicine Center (3D Lab, VinUni)

    Hanoi, 100000

    Trung Dung Tran, Professor, PhD, MD, dung.tt@vinuni.edu.vn

Other trials in Vietnam

About this study

The goal of this clinical trial is to evaluate the safety and feasibility of patient-specific bone defect implants fabricated from Ti-6Al-4V using 3D printing technology and to assess early clinical outcomes within the first 12 months following implantation of these customized devices. The main question it aims to answer is: "In patients with bone defects requiring surgical reconstruction, are patient-specific bone defect implants fabricated from titanium alloy (Ti-6Al-4V) using 3D printing technology - designed and produced at VinUni, safe and feasible for clinical use, and do they result in favorable early clinical outcomes within the first 12 months following implantation?"

Read the detailed description

Bone defects resulting from trauma, tumor resection, infection, or congenital abnormalities represent a significant clinical burden in orthopedic and reconstructive surgery worldwide. Large or complex bone defects often lead to prolonged disability, functional impairment, and reduced quality of life if not appropriately treated. According to the World Health Organization (WHO), each year there are approximately 20-50 million non-fatal road traffic injuries globally, many of which are associated with fractures and segmental bone loss requiring surgical intervention.1 In addition, age-related musculoskeletal disorders such as osteoporosis, which affects an estimated 200 million people worldwide, further increase the incidence of bone defects and fracture-related complications.2 Epidemiological studies have shown that bone loss following tumor resection, severe trauma, or chronic infection remains a major challenge due to limited regenerative capacity and high mechanical demands at defect sites. Traditional reconstruction methods, including autologous and allogeneic bone grafting, although widely applied, are associated with several limitations such as donor-site morbidity, limited graft availability, risk of infection transmission, prolonged treatment time, and difficulty in achieving optimal anatomical reconstruction.3,4 As a result, bone reconstruction using artificial implantable materials has emerged as a promising therapeutic strategy. Among available options, artificial bone implants based on metallic biomaterials, particularly titanium alloys, have gained increasing attention due to their ability to provide immediate mechanical stability and support biological integration.5-7 Titanium and titanium-based alloys have been extensively used in clinical bone implantation for several decades and are recognized as among the most reliable materials for skeletal reconstruction.5,7 These materials have demonstrated favorable mechanical strength, corrosion resistance, and excellent biocompatibility, allowing long-term implantation in the human body. Titanium implants have been successfully applied in a wide range of clinical settings, including cranial and craniofacial reconstruction, limb and long bone defect replacement, spinal fixation, and dental implantation.5 Regulatory authorities such as the U.S. Food and Drug Administration (FDA) have approved the use of titanium alloys, including Ti-6Al-4V, for implantable medical devices based on accumulated evidence of safety and effectiveness.6 Furthermore, international standards such as ISO 5832 and ISO 10993, and also Vietnamese national standard clearly define requirements for chemical composition, mechanical properties, and biocompatibility testing of titanium alloys used in medical implants.8-10 Numerous international and domestic studies have consistently reported low toxicity, minimal inflammatory response, and good osseointegration associated with titanium-based implants, thereby confirming their clinical safety and suitability for bone defect reconstruction.5-7 In recent years, additive manufacturing, commonly referred to as three-dimensional (3D) printing, has emerged as a major technological advancement in the fabrication of titanium alloy implants. Conventional manufacturing methods, such as casting, forging, or machining, often face limitations in producing complex geometries and patient-specific designs, particularly for irregular or large bone defects.6 In contrast, 3D printing technologies, especially laser-based techniques such as selective laser melting or laser powder bed fusion, enable the precise fabrication of Ti-6Al-4V implants based on individual patient anatomy.11 Using preoperative imaging data from computed tomography or magnetic resonance imaging, personalized implants can be digitally designed to closely match defect morphology. 12-15 This high level of design accuracy allows improved implant fit, optimized load transmission, and the incorporation of porous or lattice structures that enhance bone ingrowth and biological fixation.9,11 Consequently, 3D-printed titanium implants offer significant advantages in addressing complex bone defects where conventional implants may be inadequate.

Globally, a growing number of studies have investigated the clinical application of 3D-printed titanium implants in bone defect reconstruction and have reported encouraging early outcomes. International case series and clinical reports have described successful use of patient-specific 3D-printed Ti-6Al-4V implants in pelvic reconstruction following tumor resection, craniofacial and cranial defect repair, limb-salvage surgery, and complex defects of the foot and ankle.16-19 These studies have demonstrated acceptable safety profiles, satisfactory implant stability, favorable bone integration, and improvement in functional outcomes during early follow-up periods. Reviews published in international orthopedic and biomaterials journals have emphasized the advantages of personalized implant design and porous surface architecture in promoting osseointegration and functional recovery.17 In Vietnam, research and clinical implementation of 3D printing technology in bone implantation are rapidly developing, with increasing application in craniofacial surgery, orthopedic trauma, and oncology.20 However, most domestic reports remain limited to technical descriptions or isolated clinical cases, and prospective clinical studies with standardized evaluation of safety and early outcomes are still scarce.

Despite the growing international experience and emerging clinical applications in Vietnam, several critical gaps remain that justify the necessity of this study. according to the latest guidelines from the Ministry of Health, as high-risk medical devices (Class D), patient-specific 3D-printed titanium implants are required to undergo systematic clinical evaluation across Phase I, II, and III trials to rigorously demonstrate safety, feasibility, and clinical effectiveness prior to widespread clinical implementation.21 Although preliminary studies in Vietnam have investigated similar products, most available evidence remains limited to isolated cases or technical reports, with a lack of prospective, systematically designed clinical studies.22 Furthermore, differences in manufacturing systems, machine configurations, material handling, and process parameters across production facilities may substantially influence implant quality and clinical performance, thereby necessitating site-specific clinical evidence to confirm that implants fabricated at a given 3D printing laboratory are safe, feasible, and effective in patients.23,24 This study is therefore essential to address these regulatory and scientific requirements and to generate foundational clinical evidence supporting responsible clinical translation of 3D-printed titanium implants. In this context, the 3D Medical Technology Laboratory at VinUniversity serves as a site-specific manufacturing facility for patient-specific 3D-printed implants, operating in compliance with internationally recognized ISO standards for medical device production and being entrusted by the Ministry of Health, particularly the Department of Science, Technology and Training, to support clinical evaluation activities.25 This study is therefore essential to address these regulatory and scientific requirements and to generate foundational clinical evidence supporting the responsible clinical translation of 3D-printed titanium implants produced within this manufacturing system.

Being tested
Patient-specific 3D-printed Ti-6Al-4V bone implant
Keywords
Bone defect reconstruction, Patient-specific implants, Three-dimensional (3D) printing, Titanium alloy Ti-6Al-4V
Medical subject headings
Bone Diseases, Metabolic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Patient-specific 3D-printed Ti-6Al-4V bone implantDevice

    The investigational device is a patient-specific bone implant manufactured from titanium alloy Ti-6Al-4V using metal additive manufacturing technology. The implant is designed individually for each patient based on medical imaging data (CT or MRI), which are converted from DICOM format into three-dimensional digital models for anatomical reconstruction and implant design. The device is fabricated using selective laser melting (SLM) technology, in which high-power laser beams selectively fuse layers of Ti-6Al-4V powder to produce the final implant geometry. The manufacturing process is performed on a metal additive manufacturing system under an inert gas environment to prevent oxidation and ensure material integrity. Titanium powder feedstock complies with ASTM F2924 specifications for medical-grade Ti-6Al-4V used in powder bed fusion processes. Following printing, implants undergo standardized post-processing procedures including support removal, surface cleaning and finishing, stress-

Study groups in NCT07540156
Study groupRoleWhat they receive
Patient-specific 3D-printed Ti-6Al-4V implant reconstructionExperimentalParticipants in this arm will undergo surgical reconstruction of bone defects using patient-specific implants fabricated from titanium alloy (Ti-6Al-4V) through three-dimensional (3D) printing technology. Implants are designed based on preoperative imaging data (CT ± MRI) and manufactured using laser powder bed fusion/selective laser melting. The study evaluates the safety, feasibility, and early clinical outcomes of these customized implants during a 12-month follow-up period.
Receives: Device: Patient-specific 3D-printed Ti-6Al-4V bone implant

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants with Major Postoperative Complications

    Assessment of major postoperative complications related to the implant or surgical procedure (Yes/No), based on clinical examination and medical record review.

    Measured: 1-4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  2. Number of Participants with Early Local Complications

    Assessment of early local complications including wound discharge, bleeding, swelling, pain, and sensory disturbance, evaluated using standardized clinical examination.

    Measured: Within 4 weeks postoperatively

  3. Number of Participants with Early Systemic Complications

    Assessment of early systemic complications including sepsis, hemodynamic instability, and respiratory failure, based on clinical evaluation and inpatient medical records.

    Measured: Within 4 weeks postoperatively

  4. Number of Participants with Late Implant-Related Complications

    Assessment of late implant-related complications including implant loosening, sinus tract formation, and persistent pain, evaluated through clinical examination.

    Measured: From 6 weeks up to 12 months postoperatively

  5. Change in C-reactive Protein (CRP) Level

    CRP levels (mg/L) will be measured using standard laboratory blood tests as an indicator of systemic inflammatory response following implantation.

    Measured: Within 4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  6. Change in White Blood Cell (WBC) Count

    WBC count (×10⁹/L) will be measured using standard hematology tests as an indicator of infection or systemic inflammatory response.

    Measured: Within 4 weeks postoperatively and from 6 weeks up to 12 months postoperatively

  7. Operative Time

    Duration of the surgical procedure measured in minutes, recorded from surgical records.

    Measured: Intraoperative period

  8. Estimated Blood Loss

    Estimated intraoperative blood loss measured in milliliters (mL), recorded from surgical records.

    Measured: Intraoperative period

Secondary outcomes (7)
  1. Number of Participants with Implant Stability (No Implant Loosening)

    Assessment of implant stability defined as absence of implant loosening (Yes/No), evaluated by clinical examination and imaging (X-ray or CT).

    Measured: At 3, 6, and 12 months postoperatively

  2. Rate of Successful Bone-Implant Integration on Imaging

    Assessment of osseointegration based on imaging findings (X-ray or CT), defined as absence of radiolucent lines and presence of a stable bone-implant interface.

    Measured: At 3, 6, and 12 months postoperatively

  3. Number of Participants with restoration of Anatomical Structure

    Assessment of postoperative anatomical reconstruction (e.g., limb morphology) using clinical evaluation and imaging documentation.

    Measured: Postoperative period and at 12 months postoperatively

  4. Change in Pain Score Measured by Visual Analog Scale (VAS)

    Pain intensity will be assessed using the Visual Analog Scale (VAS), a standardized 0-10 scale, with higher scores indicating greater pain.

    Measured: Baseline and at 1, 3, 6, and 12 months postoperatively

  5. Change in Functional Outcome Score

    Functional outcomes will be assessed using validated patient-reported outcome measures, depending on the anatomical site of implantation:

    • Upper extremity: Disabilities of the Arm, Shoulder and Hand (DASH) score (range: 0-100; higher scores indicate greater disability and worse function)
    • Lower extremity: Lower Extremity Functional Scale (LEFS) (range: 0-80; higher scores indicate better functional status)

    Measured: Baseline and at 3, 6, and 12 months postoperatively

  6. Change in Health-Related Quality of Life (SF-36 Score)

    Health-related quality of life will be assessed using the Short Form-36 Health Survey (SF-36), a validated patient-reported outcome measure.

    The SF-36 includes eight domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health), which are summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores.

    Scores range from 0 to 100, with higher scores indicating better health-related quality of life.

    Measured: Baseline and at 12 months postoperatively

  7. Number of Participants with Limb Length Discrepancy

    Assessment of limb length discrepancy (Yes/No), evaluated using clinical examination and imaging.

    Measured: From 6 weeks up to 12 months postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2026
  2. Study start1 Apr 2026 (estimated)
  3. Primary completion30 Jun 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07540156
Sponsor's protocol ID
VINUNI-MD-2026-001
Status last verified
Jan 2026
First submitted
10 Mar 2026
Last updated
20 Apr 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Patient-specific 3D-printed Ti-6Al-4V bone implant in people with Bone Loss and Bone Defects, run by VinUniversity at 1 site in Vietnam.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Trung Dzung Tran, Professor, PhD, MD (+84983762005, dung.tt@vinuni.edu.vn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants with Major Postoperative Complications (time frame: 1-4 weeks postoperatively and from 6 weeks up to 12 months postoperatively). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in